SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
The Anopheles stephensi mosquito is a vector of malaria. (Photo: CDC/ Dr. William Collins)
With Possible 'Major Public Health Impact,' Malaria Vaccine Advances
Research publication on effectiveness of new vaccine follows announcement by pharmaceutical corporation GlaxoSmithKline that it is applying for first ever approval of anti-malaria vaccine on EU markets.
Jul 30, 2014
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
An Unconstitutional Rampage
Trump and Musk are on an unconstitutional rampage, aiming for virtually every corner of the federal government. These two right-wing billionaires are targeting nurses, scientists, teachers, daycare providers, judges, veterans, air traffic controllers, and nuclear safety inspectors. No one is safe. The food stamps program, Social Security, Medicare, and Medicaid are next. It’s an unprecedented disaster and a five-alarm fire, but there will be a reckoning. The people did not vote for this. The American people do not want this dystopian hellscape that hides behind claims of “efficiency.” Still, in reality, it is all a giveaway to corporate interests and the libertarian dreams of far-right oligarchs like Musk. Common Dreams is playing a vital role by reporting day and night on this orgy of corruption and greed, as well as what everyday people can do to organize and fight back. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
Sarah Lazare
Sarah Lazare was a staff writer for Common Dreams from 2013-2016. She is currently web editor and reporter for In These Times.
An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.
The publication follows GSK's announcement last week that it is applying for approval from European Union regulatory bodies to put the first-ever malaria vaccine on the market.
Published Tuesday in PLOS Medicine, the vaccine research followed the infection rates of 6,537 infants (6 to 12 weeks old) and 8,923 children (5 to 17 months old) who were administered the vaccine at "11 African Sites" where Malaria is prevalent.
Over the course of 18 months, the researchers found that the vaccine "averted an average of 829 and 449 cases of clinical malaria per 1,000 children and infants vaccinated, respectively."
According to the study's authors, the findings show significant effectiveness and suggest that the vaccine "could have a major public health impact in sub-Saharan Africa."
Malaria disproportionately affects poor and rural communities in the global south, hitting sub-Saharan Africa the hardest. Despite being preventable and curable if addressed promptly, the disease is a top cause of death and illness throughout the developing world, killing approximately 1.2 million people a year, the vast majority of them children.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.